USFDA Rejects Replimune’s RP1 for Advanced Melanoma, Flags Insufficient Data
Bengaluru: The U.S. ​Food and Drug Administration ​on Friday declined to approve Replimune's drug for ​advanced skin cancer citing insufficient data from studies, a letter from the regulator showed.This marks…